Get the Stockscreener App
6.56
5.20%
-0.36
Astria Therapeutics Inc stock is traded at $6.56, with a volume of 233.46K.
It is down -5.20% in the last 24 hours and up +20.81% over the past month.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
See More
Previous Close:
$6.92
Open:
$6.77
24h Volume:
233.46K
Relative Volume:
0.57
Market Cap:
$370.21M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
-2.7107
EPS:
-2.42
Net Cash Flow:
$-68.47M
1W Performance:
-1.35%
1M Performance:
+20.81%
6M Performance:
-16.54%
1Y Performance:
-41.38%
1-Day Range:
$6.52
$6.86
1-Week Range:
$6.305
$7.34
52-Week Range:
$3.555
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
Name
Astria Therapeutics Inc
Sector
Industry
Phone
617-349-1971
Address
22 BOSTON WHARF ROAD, BOSTON
Compare ATXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
6.56 | 390.52M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jul-29-24 | Initiated | TD Cowen | Buy |
| Mar-28-23 | Initiated | Evercore ISI | Outperform |
Astria Therapeutics Inc Stock (ATXS) Latest News
Astria Therapeutics Inc. stock momentum explainedSecure Entry Point Finder with Analysis - Newser
Why Astria Therapeutics Inc. stock attracts strong analyst attentionFree Weekly Stock Opportunity Radar Scanner - Newser
What makes Astria Therapeutics Inc. stock price move sharplyExpert Picks Outlook For Beginners - jammulinksnews.com
Astria Therapeutics Inc. stock prediction for this weekCommunity Picked Stocks with Trade Insights - Newser
Price action breakdown for Astria Therapeutics Inc.Smart Swing Picks with Confirmed Signals - Newser
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Rating of “Buy” from Analysts - Defense World
Price momentum metrics for Astria Therapeutics Inc. explainedMachine Learning Stock Price Forecast Tool - Newser
Will Astria Therapeutics Inc. continue its uptrendIn-Depth Stock Trading Volume Analysis - Newser
Astria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE Patients - Insider Monkey
How Astria Therapeutics Inc. stock performs during market volatilityMonthly Long-Term Market Recap and Summary - Newser
New Product Launches: Will They Boost Astria Therapeutics Inc. Stock in 2025Smart Stock Forecast Using AI Algorithms - Newser
Why is Astria Therapeutics Inc. stock attracting strong analyst attentionTop Growth Tips For Fast Growth - jammulinksnews.com
How to escape a deep drawdown in Astria Therapeutics Inc.Free Trade Insight With Community Collaboration - Newser
Volume Surge May Signal Institutional Interest in Astria Therapeutics Inc.Consistent Income Focused Trade List Analyzed - metal.it
Published on: 2025-07-29 23:13:08 - metal.it
Will Astria Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsHistorical Stock Summary and ROI Review - Newser
What are analysts’ price targets for Astria Therapeutics Inc. in the next 12 monthsMaximize portfolio value with expert tips - jammulinksnews.com
What institutional investors are buying Astria Therapeutics Inc. stockBoost your returns with professional guidance - jammulinksnews.com
Moving Average Trends for Astria Therapeutics Inc. Stock: What They IndicateFree Pattern Detection for Entry Confirmation - Newser
What are the latest earnings results for Astria Therapeutics Inc.Capitalize on stocks with high profit margins - jammulinksnews.com
What are Astria Therapeutics Inc. company’s key revenue driversAchieve breakthrough investment performance - jammulinksnews.com
What is Astria Therapeutics Inc. company’s growth strategyInvest smarter with actionable trading signals - jammulinksnews.com
How Interest Rate Changes Impact Astria Therapeutics Inc. Stock PerformanceFree Predictions - metal.it
Published on: 2025-07-28 02:50:31 - jammulinksnews.com
What are the technical indicators suggesting about Astria Therapeutics Inc.Maximize portfolio value with timely trades - jammulinksnews.com
Astria Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowHigh Return Stock Alerts - Newser
What catalysts could drive Astria Therapeutics Inc. stock higher in 2025Achieve rapid portfolio appreciation - jammulinksnews.com
Is Astria Therapeutics Inc. a growth stock or a value stockGet real-time alerts on high-potential stocks - jammulinksnews.com
Astria Therapeutics Inc. Stock Analysis and ForecastFree Stock Index Interpretation - PrintWeekIndia
What analysts say about Astria Therapeutics Inc. stockFree Stock Market Forecast Reports - Autocar Professional
What drives Astria Therapeutics Inc. stock priceConsistent double returns - Autocar Professional
Is Astria Therapeutics Inc. a good long term investmentFree Market Dynamics Reports - jammulinksnews.com
Astria Therapeutics Inc Stock (ATXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):